Industry Research by Koncept Analytics
Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook ----------------------------------------(2017-2021) May 2017
Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)
1
Executive Summary Iron is among the vital minerals present in the human body. It is one of the components of hemoglobin, the substance present in red blood cells that carries oxygen throughout the body through blood, and oxygen is further utilized by the cells to produce energy required to perform all the required functions. Therefore, decline in the body’s supply of iron can lead to severe problems. The balance of iron in the body primarily is a combined result of three dynamics- intake, losses and metabolic demand. Intravenous (I.V.) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous (I.V.) drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body. The report “Global I.V. Iron Drugs Market� provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry, Galenica Group, AMAG Pharmaceuticals and Allergan are being profiled. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth. The key factors driving the growth of I.V. iron drugs market are growing ageing population, growing urbanization, increase in number of dialysis cases, rising healthcare expenditure and increasing life expectancy rate. Some of the noteworthy trends and developments of this industry are paradigm shift from oral iron drugs to intravenous iron drugs and introduction of first generation drugs InFeD and Dexeferrum. However, the expansion of the market is hindered by potential risks of I.V. iron.
Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)
2
Rising incidence of chronic kidney disease (CKD), iron deficiency to drive the market Global I.V. Iron Drugs Market by Value (2010-2016) ▪ The global I.V. iron market was valued at US$... million in 2016, up by …%, as compared to US$... million in 2015. ▪ As of 2016, Ferinject remained the gold standard product in dialysis patients with …% of the global I.V. iron market share followed by Venofer and ISS with …% and …% share respectively. ▪ The ferric carboxymaltose segment accounted for the majority market share of …% during 2016. It was followed by sucrose and dextran with share of …% and …% respectively.
Global I.V. Iron Drugs Market Share by Product Category (2016)
Global I.V. Iron Drugs Market Share by Segments (2016)
Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)
3
The market growth was primarily driven by Venofer and Ferinject. The US I.V. Iron Drug Market by Value (2010-2016) ▪ The US I.V. iron drug market increased to US$... million in 2016 from US$... million in 2015, showing an increase of …%. ▪ The size of the total 2016 US non-dialysis IV iron replacement therapy market was approximately… million grams. ▪ European I.V. iron drug market was valued at US$... million in 2016, as compared to US$... million in 2015, representing a growth of …%.
The US Non-dialysis I.V. Iron Drug Market by Volume (2010-2016)
European I.V. Iron Drug Market by Value (20102016)
Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)
4
Contact Us:
Disclaimer
This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report. We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T: +91-120-4130959 M: +91-9811715635 vikas@konceptanalytics.com www.konceptanalytics.com
Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)
5